![Konstantinos Efthymiopoulos](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Konstantinos Efthymiopoulos
Presidente presso SynAffix BV
Posizioni attive di Konstantinos Efthymiopoulos
Società | Posizione | Inizio | Fine |
---|---|---|---|
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Presidente | 07/01/2016 | - |
Independent Dir/Board Member | 07/01/2016 | - |
Storia della carriera di Konstantinos Efthymiopoulos
Precedenti posizioni note di Konstantinos Efthymiopoulos
Società | Posizione | Inizio | Fine |
---|---|---|---|
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Fondatore | 18/06/2010 | - |
Farmitalia Carlo Erba SRL | Corporate Officer/Principal | - | - |
Glaxo, Inc. | Corporate Officer/Principal | - | - |
Glaxo Wellcome, Inc. | Corporate Officer/Principal | - | - |
Eurand, Inc.
![]() Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Direttore Tecnico/Scientifico/R&S | - | - |
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Presidente | - | - |
Formazione di Konstantinos Efthymiopoulos
University of Strasbourg | Doctorate Degree |
National & Kapodistrian University of Athens | Graduate Degree |
University of London | Masters Business Admin |
Statistiche
Distribuzione geografica
Regno Unito | 4 |
Stati Uniti | 3 |
Francia | 2 |
Posizioni
Corporate Officer/Principal | 3 |
Graduate Degree | 2 |
President | 1 |
Settori
Health Technology | 7 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 7 |
---|---|
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Eurand, Inc.
![]() Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Health Technology |
Glaxo Wellcome, Inc. | Health Technology |
Glaxo, Inc. | |
Farmitalia Carlo Erba SRL | Health Technology |
Epsilon-3 Bio Ltd
![]() Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |